Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19

BACKGROUND: Considering the threat of the COVID-19 pandemic, caused by SARS-CoV-2, there is an urgent need to develop effective treatments. At present, neutralizing antibodies and small-molecule drugs such as remdesivir, the most promising compound to treat this infection, have attracted considerabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Tianchuan, Xiao, Yuchen, Meng, Xiaojun, Tang, Lantian, Li, Bin, Zhao, Zhaoyan, Tan, Qingqin, Shan, Hong, Liu, Lei, Huang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614633/
https://www.ncbi.nlm.nih.gov/pubmed/34823562
http://dx.doi.org/10.1186/s12951-021-01148-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614633/
https://www.ncbi.nlm.nih.gov/pubmed/34823562
http://dx.doi.org/10.1186/s12951-021-01148-0

Ejemplares similares